One hypothesis is that for NSCLC patients with both EGFR mutation and concomitant non-EGFR genetic alterations, combination therapy inhibits the EGFR pathway and also counteracted the bypass activation associated with the concomitant alterations, thereby achieving better efficacy. Here, EGFR is linked to non-small cell lung carcinoma.